Navigation Links
Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007

unrestricted educational grant from Amylin Pharmaceuticals. 2. "The Role of Incretin-Based Therapies: Reconstructing Treatment Approaches in Type 2 Diabetes." This medical education symposium will help healthcare providers understand the role of incretin-based therapies in relation to type 2 diabetes. The event will be chaired by Bernard Zinman, M.D. on Monday, June 25 at 5:30 AM CT (6:30 AM ET). This symposium is supported by an unrestricted educational grant from Amylin Pharmaceuticals and Eli Lilly and Co.

Amylin will also conduct a webcast for investors to review the information presented at ADA on Sunday, June 24 at 7:30 PM CT (8:30 PM ET). The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately 15 minutes prior to the presentation to register and download any necessary audio software.


    More information about ADA can be found at

http://scientificsessions.diabetes.org.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,700 employees nationwide. For more information about Amylin visit




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:5/23/2013)... DIEGO , May 23, 2013 Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... 38 th Annual dbAccess Health Care Conference in Boston.   ... May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. ... accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... 2013  Haemonetics Corporation (NYSE: HAE ) announced ... EVP-Business Development, will present at The Deutsche Bank 38 th ... MA on May 29, 2013 at 1:30pm Eastern ... The public may access Mr. Lindop,s presentation live via ... Haemonetics (NYSE: HAE ) is a ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
... Patients with active moderate to severe rheumatoid arthritis ... or adalimumab (Humira ® ) and who were actively ... from baseline at week 10, and sustained response through ... 26 results from the RESTART study were presented for ...
... LLC, the image analysis and pattern recognition technology provider, ... of $244,479.25 under the U.S. Government,s Affordable Care Act. ... projects that show significant potential to produce new therapies, ... health care costs or advance the goal of curing ...
Cached Medicine Technology:New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government 2
(Date:5/25/2013)... On May 20, 2013 the Sydney ... to discuss or plan for their eventual demise, but it ... released a Must-Do List to help people properly arrange for ... a personal fact sheet.” , While not a formal document, ... personal data. It may include a summary of assets, ...
(Date:5/25/2013)... 25, 2013 According to a ... Market, 2013–2018", published by MarketsandMarkets is expected to ... of 5.54% which analyzes and studies the major ... Europe, Asia, and Rest of the World. , ... Tables , 87 Figures , ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The Slim Weight ... effectiveness and results. This is due to the highly sought ... patches. Slim weight patch offers an extra 2 months supply ... fitness goals and get the body you desire faster than ... Official Website , With Slim weight patch consumers can ...
(Date:5/25/2013)... May 25, 2013 Ayurveda is ... means "knowledge or wisdom of life". While a medical science, ... the transformation of consciousness. Its fundamental philosophy is that disease ... our environment. It believes that in order to re-establish optimal ... harmony and then adopt a life style which brings us ...
(Date:5/25/2013)... OH (PRWEB) May 25, 2013 The ... filed an Imprelis lawsuit on behalf of 23 ... no. N13C-04-280 EMD) was filed on April 25, 2013 and ... As with previously filed Wright & Schulte Imprelis lawsuits, this ... New Castle County. , This Imprelis lawsuit ...
Breaking Medicine News(10 mins):Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Nationwide Who Allege Imprelis Use Resulted In Extensive Tree Damage and Death, Reports Wright & Schulte 2Health News:Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Nationwide Who Allege Imprelis Use Resulted In Extensive Tree Damage and Death, Reports Wright & Schulte 3Health News:Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Nationwide Who Allege Imprelis Use Resulted In Extensive Tree Damage and Death, Reports Wright & Schulte 4
... & Lomb, the global eye health company, has entered ... for the development of certain intraocular lens (IOL) materials. ... has obtained the rights to Santen,s hydrophobic acrylic polymers, ... worldwide. Santen reserves the right for the use of ...
... March 3 Marinus Pharmaceuticals, Inc. today announced that ... clinical trial investigating the safety and efficacy of ganaxolone ... a type of epilepsy. In this trial, ganaxolone ... Efficacy was seen in the first week of ...
... supplies has unveiled their annual 2009 list of what to do if ... ... Nationwide Medical/Surgical , a distributor of the flu vaccine and flu ... if exposed to the flu virus., , ,The flu is a highly ...
... Study finds it alters levels of hormones, could raise risk ... 2 -- Working the night shift might lead to hormonal ... heart disease, researchers say. , "In the long run, the ... the regulation of body weight -- leptin, insulin, cortisol -- ...
... KIRKLAND, Wash., Feb 26 ProteoTech Inc. announced ... from The Michael J. Fox Foundation for Parkinson,s ... (Philadelphia, PA), ProteoTech scientists will utilize ProteoTech,s small ... agents that will allow doctors to use PET ...
... 2 Speaker Nancy Pelosi released the following ... Sebelius as Secretary of the Department of Health and ... leader who has worked to expand health care access ... drugs. "Governor Sebelius, deep understanding of health care issues ...
Cached Medicine News:Health News:Bausch & Lomb, Santen Strike Licensing Agreement for IOL Development 2Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 2Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 3Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 4Health News:Nationwide Medical/Surgical Reveals Their Help Sheet For Those Infected with Influenza Virus 2Health News:Night Shift Work Hard on the Heart 2Health News:Night Shift Work Hard on the Heart 3Health News:ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain 2
The Cygnus-PFS Image-Guided Surgery System is the world's first portable and affordable image-guided surgery system....
Used to negotiate tortuous vessels....
Used for complex diagnostic and interventional procedures....
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
Medicine Products: